Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death
Open Access
- 26 January 2018
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 9 (2) , 138
Abstract
Drug combinations have been increasingly applied in chemotherapy as a strategy to enhance the efficacy of anti-cancer treatment. The appropriate drug combinations may achieve synergistic effects beyond monotherapies alone. AC220 (Quizartinib), an FLT3 receptor tyrosine kinase inhibitor, developed for the treatment of AML, has been tested in phase II human clinical trials. However, AC220 as a monotherapy is not efficacious enough. In this study, we performed a small-molecule screening of 12 640 compounds in order to find a compound that increase the AC220 efficacy in chemotherapy. We identified that TAK-165, a HER2 inhibitor, even when used at low nanomolar doses in combination with AC220, was able to induce cell death in different cancer cells, but not in non-cancer cell lines. We showed that TAK-165 and AC220 act synergistically to downregulate key signaling pathways and potently induce cancer cell death. Furthermore, we demonstrated that TAK-165 inhibited autophagy in a HER2-independent manner. Finally, we showed that the combination of TAK-165 and AC220 induced cell death in cancer cells through the activation of chaperone-mediated autophagy. Overall, these findings support the strategy for using AC220 and an autophagy inhibitor such as TAK-165 in a combinatorial treatment to enhance the efficacy of cancer therapies.Keywords
This publication has 71 references indexed in Scilit:
- Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatmentCell Death & Disease, 2013
- Discovery of small molecule cancer drugs: Successes, challenges and opportunitiesMolecular Oncology, 2012
- Autophagy: assays and artifactsThe Journal of Pathology, 2010
- mTOR regulation of autophagyFEBS Letters, 2010
- Chaperone‐mediated autophagy in health and diseaseFEBS Letters, 2009
- Synergistic drug combinations tend to improve therapeutically relevant selectivityNature Biotechnology, 2009
- Role of autophagy in cancerNature Reviews Cancer, 2007
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- The role of autophagy in cancer development and response to therapyNature Reviews Cancer, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005